Amongst sufferers with PD-1/PD-L1-pretreated recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), remedy with buparlisib and paclitaxel was not related to an enchancment in general survival (OS) in contrast with paclitaxel alone, scientific trial outcomes have proven.
Section 3 outcomes of the BURAN trial have been introduced in the course of the 2025 ESMO Congress in Berlin.
Findings confirmed that the median OS with buparlisib plus paclitaxel was 9.6 months in contrast with 9.7 months with paclitaxel alone on this affected person inhabitants.
Glossary
General survival: The size of time from the beginning of remedy that sufferers are nonetheless alive.
General response price: The share of sufferers whose most cancers shrinks or disappears after remedy.
Development-free survival: The size of time throughout and after remedy {that a} affected person lives with most cancers with out it getting worse.
ECOG efficiency standing: A scale docs use to measure how a affected person’s sickness impacts their each day residing and skill to take care of themselves.
“The buparlisib plus paclitaxel mixture arm has a numerically increased general response price, however there was no improve in progression-free survival in comparison with the paclitaxel-only arm,” lead examine creator Dr. Denis Souliéres, full professor of medication on the Université de Montréal, Canada, mentioned in an oral presentation in the course of the assembly. “Translational information will allow to discover if molecular subgroups derive vital profit.”
Buparlisib is an oral pan-PI3K inhibitor that targets all 4 isoforms of sophistication 1 PI3K. Prior part 1b information confirmed that buparlisib and paclitaxel confirmed scientific exercise in sufferers with taxane-pretreated superior stable tumors. Moreover, information from the part 2 BERIL-1 trial confirmed a progression-free survival (PFS) enchancment with buparlisib and paclitaxel versus placebo and paclitaxel, in addition to an OS enchancment in sufferers with recurrent or metastatic squamous cell carcinoma of head and neck who skilled failure of 1 prior platinum-based remedy.
To be eligible for enrollment, sufferers needed to have recurrent or metastatic HNSCC and have obtained a previous PD-1/PD-L1 inhibitor within the recurrent/metastatic setting, one to 2 prior traces of remedy, and an ECOG efficiency standing of 0 or 1.
A complete 487 sufferers have been randomly assigned between April 2021 and November 2023 to obtain buparlisib at 100 mg as soon as each day plus paclitaxel at 80 mg/m2 on days 1, 8, and 15 each three weeks or paclitaxel alone on the similar dosage.
Most sufferers who discontinued the mixture (98.5% for each brokers) did so due to illness development (buparlisib, 38.7%; paclitaxel, 39.9%) adopted by unwanted effects (38.1%; 35.6%). Within the paclitaxel-alone arm, 98.8% of sufferers discontinued paclitaxel on account of illness development (54.9%) and unwanted effects (17.7%).
Relating to baseline traits throughout each arms, 29.8% of sufferers have been HPV constructive, roughly half have been from Europe (50.1%), and the bulk have been male (80.3%). The median age was 61.5 years, and 63.4% have been White; most weren’t Hispanic or Latino (85.6%). HPV positivity solely of the oropharynx was in 19.8% of sufferers who obtained the buparlisib mixture and 17.7% of those that obtained chemotherapy alone.
A complete 42.4% and 39% of sufferers, respectively, beforehand obtained a PD-1/PD-L1 inhibitor alone or together with non–platinum-based remedy, whereas 39.3% and 45.1% of sufferers obtained the immunotherapy concurrently with platinum-based chemotherapy. A complete 16.7% and 15.9% of sufferers obtained them in sequence with platinum-based chemotherapy. Moreover, 70% and 68.3% of sufferers on buparlisib and paclitaxel alone, respectively, had metastatic illness at examine entry.
Extra efficacy information confirmed that the confirmed ORR was 30.3% with buparlisib/paclitaxel in contrast with 20.7% with paclitaxel alone; the unconfirmed ORRs have been 44.3% and 28%, respectively. When assessed by way of investigator, the confirmed ORRs have been 29.7% versus 24.4% and unconfirmed ORRs have been 44.6% and 28%.
The median DOR was 5.6 months with buparlisib versus 9.1 months with paclitaxel alone; per investigator evaluation, the median DOR was 7 months versus 6.7 months, respectively.
The median PFS was 4.1 months in every arm by investigator evaluation, the median PFS was 4.3 months in contrast with 4.2 months, respectively.
Relating to security, grade 3 (extreme) or increased unwanted effects occurred in 87.5% and 59.4% of sufferers of the mixture versus paclitaxel alone arms; treatment-related grade 3 or increased unwanted effects have been reported in 71% and 33.8%, respectively. A complete 60.1% of those unwanted effects have been associated to buparlisib; 60.4% have been paclitaxel associated within the mixture arm versus 33.8% within the monotherapy arm.
Unwanted side effects that led to review drug discontinuation occurred in 45.2% and 16.9% of sufferers within the buparlisib mixture and paclitaxel alone teams, respectively. A complete 37.7% of these within the mixture group have been buparlisib associated; on the mixture arm, 35.2% have been associated to paclitaxel, and 16.9% have been associated to paclitaxel on the monotherapy arm. Unwanted side effects of particular curiosity occurred in 88.2% and 75% of sufferers, respectively.
Souliéres famous that there have been no traits that have been a consider OS enchancment with the mixture versus paclitaxel alone, apart from a possible survival benefit in sufferers with HPV-positive oropharynx most cancers versus different HPV standing and first website of most cancers. North American sufferers additionally had a considerably increased OS benefit with buparlisib/paclitaxel in contrast with Asian Pacific sufferers and European sufferers.
“There have been extra HPV-positive sufferers that have been North American sufferers in comparison with what we noticed in Asia and Europe, however I’ll remind you that the HPV positivity didn’t particularly translate into an OS within the general evaluation,” Souliéres commented.
Souliéres concluded that the immunotherapy-refractory HNSCC affected person inhabitants stays one with vital unmet want.
References
- “BURAN: A part III examine of buparlisib (BUP) plus paclitaxel (PAC) in sufferers with PD-1(PD-L1)-pretreated recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC),” Dr. Denis Souliéres, et al., introduced at: 2025 ESMO Congress; October 17-21, 2025; Berlin, Germany. Summary LBA48.
- Section lb examine of buparlisib (BKM120) plus both paclitaxel (PTX) in superior stable tumors (aST) or PTX plus trastuzumab (TZ) in HER2+ breast most cancers (BC),” Dr. Cristina Cruz Zambrano, et al., J Clin Oncol.
- “Buparlisib and paclitaxel in sufferers with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the pinnacle and neck (BERIL-1): a randomised, double-blind, placebo-controlled part 2 trial,” Dr. Denis Souliéres, et al. Lancet Oncol. 2017;18(3):323-335. doi:10.1016/S1470-2045(17)30064-5
For extra information on most cancers updates, analysis and training,
